Assembly Biosciences, Inc. (ASMB)

Market Cap	79.69M
Revenue (ttm)	28.52M
Net Income (ttm)	-40.18M
Shares Out	7.50M
EPS (ttm)	-6.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,735
Open	10.93
Previous Close	10.90
Day's Range	10.61 - 11.06
52-Week Range	10.27 - 19.93
Beta	0.63
Analysts	Strong Buy
Price Target	33.00 (+210.73%)
Earnings Date	Mar 20, 2025

About ASMB

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-g...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2010
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: ASMB
• Website: https://www.assemblybio.com

Financial Performance

In 2024, Assembly Biosciences's revenue was $28.52 million, an increase of 298.16% compared to the previous year's $7.16 million. Losses were -$40.18 million, -34.38% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price forecast is $33.0, which is an increase of 210.73% from the latest price.

Price Target

$33.0

(210.73% upside)

Analyst Consensus: Strong Buy